Last reviewed · How we verify
NCT04871893: multiECCO2R
Safety and Efficacy Evaluation of CO2 Removal in Combination With Continuous Veno-Venous Hemodialysis/Hemodiafiltration Therapy
NA trial testing multiECCO2R blood-gas exchanger in Acute Lung Injury in 28 participants. Completed in 31 December 2024.
6 December 2024
Quick facts
| Lead sponsor | Fresenius Medical Care Deutschland GmbH |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 28 |
| Start date | 25 March 2022 |
| Primary completion | 6 December 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 6 locations across Germany |
Drugs / interventions tested
- multiECCO2R blood-gas exchanger
Conditions studied
- Acute Lung Injury — all drugs for Acute Lung Injury →
- Acute Kidney Injury — all drugs for Acute Kidney Injury →
- Hypercapnia — all drugs for Hypercapnia →
- Covid19 — all drugs for Covid19 →
Sponsor
Fresenius Medical Care Deutschland GmbH — full company profile →
Who can join
18 and older, any sex, with Acute Lung Injury or Acute Kidney Injury. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Objective of the study is to assess the safety and efficacy of CO2 removal by the multiECCO2R (CO2 Removal System) on the multiFiltrate/multiFiltrate Pro in veno-venous extracorporeal circulation during continuous renal replacement therapy (CRRT) in patients presenting with hypercapnia due to acute lung failure and acute kidney injury.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04871893
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Lung Injury
Currently open trials in the same condition.
- NCT05704166 — PirfenidoneVsPlacebo as Prophylaxis Against Acute Radiation-induced Lung Injury Following HFRT in Breast Cancer Patients · Phase 2 · recruiting
Other Fresenius Medical Care Deutschland GmbH trials
Trials by the same sponsor.
- NCT06236984 — Retrospective Data Analysis of CKRT (Continuous Kidney Replacement Therapy) Treatments in Adult Mode With multiFiltrateP · completed
- NCT05441020 — Development, Feasibility Testing and Validation of a Survey Set to Measure Patient-Reported Outcomes Among Hemodialysis · completed
- NCT05315817 — Safety and Performance Evaluation of multiPlus Dialysate During CRRT · NA · terminated
- NCT05142501 — Observation of the Immune Response After COVID-19 Additional Vaccine Doses in Chronic Patients in Hemodialysis Therapy · terminated
- NCT05081648 — Must Cannulation Technique of Vascular Access in Patients Undergoing Haemodialysis: Contributions for a Safe Nursing Int · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04871893 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fresenius Medical Care Deutschland GmbH
- Last refreshed: 28 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04871893.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing